Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
← catalyst calendarNCT07563881 · readout ≤ 1,077 d
Sponsored by Rapport Therapeutics Inc. (industry) · RAPP — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
333estimated
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-05 | actual | When the study began enrolling |
| Primary completion | Jul 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Focal Seizure
- Epilepsy
- Focal Epilepsy
Interventions
- Drug: RAP-219
- Drug: RAP-219
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFMedian Percent Change in Seizure Frequency
measured End of double-blind treatment period (end of week 14) vs Baseline
Permalink · RAPP's whole pipeline · Catalyst calendar · Every registered study · What changed